Canadian cost-effectiveness analysis of anastrozole versus tamoxifen in early breast cancer.

被引：0
|
作者：
Verma, S
Rocchi, A
Cheung, S
机构：
[1] Ottawa Reg Canc Ctr, Ottawa, ON K1Y 4K7, Canada
[2] Axia Res, Hamilton, ON, Canada
[3] AstraZeneca, Mississauga, ON, Canada
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2003年 / 82卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
648
引用
收藏
页码：S157 / S157
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of anastrozole versus tamoxifen as adjuvant therapy in early breast cancer (EBC) - a German health economic analysis
    Lux, M. P.
    Benedict, A.
    Buchholz, S.
    Woeckel, A.
    Harbeck, N.
    Kreienberg, R.
    Kaufmann, M.
    Beckmann, M. W.
    Jonat, W.
    Hadji, P.
    Distler, W.
    Raab, G.
    Tesch, H.
    Weyers, G.
    Schneeweiss, A.
    Possinger, K.
    [J]. CANCER RESEARCH, 2009, 69 (02) : 380S - 380S
  • [2] COST-EFFECTIVENESS OF ANASTROZOLE, IN COMPARISON WITH TAMOXIFEN, IN THE ADJUVANT TREATMENT OF EARLY BREAST CANCER IN BRAZIL
    Fonseca, Marcelo
    Araujo, Gabriela T. B.
    Saad, Everardo D.
    [J]. REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2009, 55 (04): : 410 - 415
  • [3] Cost-effectiveness projections of anastrozole vs. tamoxifen as initial adjuvant therapy in ER-positive early breast cancer.
    Hillner, BE
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S156 - S156
  • [4] Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal hormone-receptor positive advanced breast cancer.
    Sobocki, P.
    Borgstrom, F.
    Kasteng, F.
    Paulsson, T.
    Lidgren, M.
    Henriksson, R.
    Lundkvist, J.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S230 - S230
  • [5] Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer
    Simons, WR
    Jones, D
    Buzdar, A
    [J]. CLINICAL THERAPEUTICS, 2003, 25 (11) : 2972 - 2987
  • [6] Comparison of cost-effectiveness of aromatase inhibitors letrozole, anastrozole or exemestane versus tamoxifen for early breast cancer in hormone receptor-positive postmenopausal women: Canadian perspective
    El Ouagari, K.
    Kamon, J.
    Kaura, S.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 210 - 211
  • [7] Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial
    Boccardo, F.
    Rubagotti, A.
    Guglielmini, P.
    Fini, A.
    Paladini, G.
    Mesiti, M.
    Rinaldini, M.
    Scali, S.
    Porpiglia, M.
    Benedetto, C.
    Restuccia, N.
    Buzzi, F.
    Franchi, R.
    Massidda, B.
    Distante, V.
    Amadori, D.
    Sismondi, P.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : VII10 - VII14
  • [8] Applying survival based cost-effectiveness analyses to estimate the impact of patent expiry on the cost-effectiveness of letrozole and anastrozole versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer
    Karnon, J.
    Kaura, S.
    [J]. EJC SUPPLEMENTS, 2010, 8 (03): : 66 - 66
  • [9] A cost-effectiveness analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with early-stage breast cancer in Mexico
    Mould-Quevedo, J.
    Tapia-Valencia, J.
    Davila-Loaiza, G.
    [J]. VALUE IN HEALTH, 2007, 10 (03) : A124 - A125
  • [10] Cost-effectiveness of extended adjuvant letrozole after five years of tamoxifen in postmenopausal early breast cancer.
    Karnon, J
    Johnston, SRD
    Delea, TE
    Smith, RE
    Brandman, J
    Sung, JC
    Goss, PE
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 530S - 530S
12345